Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05245786 · ClinicalTrials.gov registry record · Early Phase 1
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
A Early Phase 1 study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05245786 is a Early Phase 1 study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8 that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 15 participants, below the 116-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05245786, a Early Phase 1 study of Stage III Rectal Cancer AJCC v8 and Stage IIIA Rectal Cancer AJCC v8, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who are undergoing chemotherapy and radiotherapy. Using 64Cu-labeled M5A positron emission tomography imaging may play a significant role in imaging patients with colorectal cancer.
Conditions Studied
Interventions
- PROCEDURE Imaging Technique
- BIOLOGICAL Copper Cu 64 Anti-CEA Monoclonal Antibody M5A
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2026-11-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05245786
The ClinicalTrials.gov registry entry for NCT05245786 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 15 other Stage III Rectal Cancer AJCC v8 trials with a reported enrollment target (87% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage III Rectal Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Imaging Technique is the first listed.
NCT05245786 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05245786 about?
NCT05245786 is a clinical study titled "An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer". This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who are undergoing chemotherapy and radiotherapy. Using 64Cu-labeled M5A pos...
What is the current status of trial NCT05245786?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2022-08-31. Estimated completion is 2026-11-12.
What conditions does trial NCT05245786 study?
This clinical trial studies the following conditions: Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Locally Advanced Rectal Carcinoma.
What interventions are being tested in trial NCT05245786?
The interventions under investigation include: Imaging Technique (PROCEDURE), Copper Cu 64 Anti-CEA Monoclonal Antibody M5A (BIOLOGICAL).
Who is sponsoring clinical trial NCT05245786?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05245786 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Rectal Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
RECRUITING · Early Phase 1
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
RECRUITING · Phase 1
-
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
RECRUITING
-
Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer
RECRUITING · Phase 1
-
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Stage III Rectal Cancer AJCC v8
All registered trials for this condition
Stage IIIA Rectal Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.